2-戊基-哌嗪 | 6303-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-戊基-哌嗪
• 英文名称: 2-Pentyl-piperazin
• 英文别名: 2-pentyl-piperazine；2-Pentylpiperazine
• CAS: 6303-79-3
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: WLXHHSGICQMPRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  苯甲酰氯 、 2-戊基-哌嗪 在 正丁基锂 、 三乙基氯硅烷 作用下， 以 四氢呋喃 为溶剂， 反应 1.67h， 以99%的产率得到N-(benzoyl)-2-pentylpiperazine
  参考文献：
  名称：

  不对称哌嗪的区域选择性单苯甲酰化。

  摘要：

  DOI：

  10.1021/jo000005e

文献信息

• [EN] SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS<br/>[FR] PIPÉRAZINES SUBSTITUÉES EN TANT QU'ANTAGONISTES DE CB1
  申请人：SCHERING CORP

  公开号：WO2009005645A1

  公开（公告）日：2009-01-08

  Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  化合物式(I)或其药用可接受的盐、溶剂合物或酯，可用于治疗由CB1受体介导的疾病或症状，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠道疾病和心血管疾病。
• SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS
  申请人：Gilbert Eric J.

  公开号：US20130072468A1

  公开（公告）日：2013-03-21

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB 1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式(I)的化合物或其药用可接受的盐、溶剂合物或酯类物，在治疗由CB1受体介导的疾病或症状方面具有用处，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（如戒烟）、胃肠道疾病和心血管疾病。
• Amido compounds and their use as pharmaceuticals
  申请人：Yao Wenqing

  公开号：US20050288317A1

  公开（公告）日：2005-12-29

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂、矿物皮质激素受体（MR）的拮抗剂以及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性以及醛固酮过量相关的各种疾病。
• Novel method for the preparation of piperazine and its derivatives
  申请人：——

  公开号：US20020095038A1

  公开（公告）日：2002-07-18

  A novel method for the synthesis of piperazine and its derivatives of formula 1, 1 wherein R is selected from hydrogen, or a lower alkyl group having 1 to 6 carbon atoms or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; R 1 is selected from hydrogen, a methyl group, a phenyl group optionally substituted with an alkyl group having 1 to 6 carbon atoms, or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; and R 2 is selected from hydrogen, or a methyl group, or a fluoromethyl group; 2 comprising the steps: a. reacting an ester of formula 11 with substituted or unsubstituted ethylenediamine of formula 7 to give 3,4-dehydropiperazine-2-one and its derivatives of formula 12, wherein R, R 1 , R 2 are as defined above and R 6 is a C 1 to C 4 linear or branched alkyl group; and b. reacting the 3,4-dehydro-piperazine-2-one and its derivatives of formula 12 with a reducing agent to yield the piperazine and its derivatives of formula 1.

  一种合成1,1-哌嗪及其衍生物的新方法，其中R选择氢，或者具有1至6个碳原子的低级烷基基团或苯基烷基基团，其烷基具有1至4个碳原子; R1选择氢、甲基、苯基（可选地带有1至6个碳原子的烷基基团）或苯基烷基基团，其烷基具有1至4个碳原子; R2选择氢、甲基或氟甲基; 2包括以下步骤：a. 反应式11的酯与式7的取代或未取代的乙二胺反应，得到式12的3,4-去氢哌嗪-2-酮及其衍生物，其中R，R1，R2如上所定义，R6为C1至C4线性或支链烷基基团; b. 反应式12的3,4-去氢哌嗪-2-酮及其衍生物与还原剂反应，得到式1的哌嗪及其衍生物。
• CYANOISOQUINOLINE
  申请人：Kehler Jan

  公开号：US20090075988A1

  公开（公告）日：2009-03-19

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。该发明提供了一种含有本发明化合物的治疗有效量和药学可接受载体的制药组合物。本发明还提供了一种制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向受试者注射式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向受试者注射式I化合物的治疗有效量。